scholarly journals 4CPS-342 Transient valproic acid toxicity: hyperammonaemia in a paediatric patient

2021 ◽  
Author(s):  
F Gomez De Rueda ◽  
B Cancela Diez ◽  
M Cardenas Anton ◽  
J De La Cruz Moreno
Keyword(s):  
Valproic Acid ◽  
Paediatric Patient ◽  
Acid Toxicity

Unresponsiveness to Human Recombinant Erythropoietin in an Epileptic Dialysis Patient Secondary to Valproic Acid Toxicity

1992 ◽  
Vol 26 (9) ◽  
pp. 1156-1156 ◽  
Author(s):  
Cem Sungur ◽  
Arzu Sungur ◽  
Tekin Akpolat ◽  
Unal Yasavul ◽  
Cetin Turgan ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Dialysis Patient ◽  
Recombinant Erythropoietin ◽  
Human Recombinant Erythropoietin ◽  
Acid Toxicity

scholarly journals Role of Carnitine in Valproic Acid Toxicity

2003 ◽  
Vol 41 (6) ◽  
pp. 899-899 ◽  
Author(s):  
Alberto Perez ◽  
Charles A. McKay
Keyword(s):  
Valproic Acid ◽  
Acid Toxicity

ISONIAZID-INDUCED VALPROIC-ACID TOXICITY, OR VICE VERSA

The Lancet ◽  
1987 ◽  
Vol 330 (8551) ◽  
pp. 152 ◽  
Author(s):  
U. Dockweiler
Keyword(s):  
Valproic Acid ◽  
Acid Toxicity

Valproic acid toxicity

Reactions ◽  
1988 ◽  
Vol 218 (1) ◽  
pp. 4-4
Keyword(s):  
Valproic Acid ◽  
Acid Toxicity

scholarly journals VALPROIC ACID TOXICITY INDUCED BY LACOSAMIDE: A RARE CASE REPORT

2017 ◽  
Vol 10 (9) ◽  
pp. 1 ◽  
Author(s):  
Karthika Ashok Kumar ◽  
Chanshi Chandran ◽  
Remya Reghu
Keyword(s):  
Valproic Acid ◽  
Case Report ◽  
Rare Case ◽  
Hyperammonemic Encephalopathy ◽  
Rare Case Report ◽  
Acid Toxicity

Valproic acid is commonly used in the treatment of both focal and generalized epilepsies and is often tolerated well.Valproic acid is usually tolerated well, but serious complications, including hepatotoxicity and hyperammonemic encephalopathy, may occur. Here we report a case of valproic acid induced hyperammonemic encephalopathy on concomitant use with lacosamide. 

Lacosamide-associated Valproic Acid Toxicity Following Febrile Illness

2016 ◽  
Vol 24 (2) ◽  
pp. 63-66
Author(s):  
백지혜 ◽  
변정혜 ◽  
은백린 ◽  
김건하 ◽  
은소희
Keyword(s):  
Valproic Acid ◽  
Febrile Illness ◽  
Acid Toxicity

Managing valproic acid toxicity-related hyperammonaemia: an unpredicted course

2021 ◽  
Vol 14 (4) ◽  
pp. e241547
Author(s):  
Sandeep Pagali ◽  
Christopher Edquist ◽  
Nicholas O'Rourke
Keyword(s):  
Valproic Acid ◽  
Case Report ◽  
First Case ◽  
Intermittent Haemodialysis ◽  
Symptom Relapse ◽  
Acid Toxicity ◽  
Chronic Use

A 20-year-old woman presented following an intentional overdose of valproic acid. Use of valproic acid, either acute or chronic, can result in hyperammonaemia. Mild hyperammonaemia with chronic use is mostly asymptomatic but can also present with concern for encephalopathy. Acute valproic acid toxicity results in significant hyperammonaemia, which can contribute to encephalopathy. Levocarnitine is the treatment of choice in valproic acid toxicity-related hyperammonaemia. For severe cases of encephalopathy, intermittent haemodialysis can also be considered. To our knowledge, this is the first case report to clearly show symptom relapse and hyperammonaemia after discontinuing levocarnitine. We recommend levocarnitine therapy for at least 72 hours, followed by an additional 24 hours of monitoring for symptom relapse and hyperammonaemia after levocarnitine discontinuation.

Levocarnitine-Induced Hypophosphatemia in a Hemodialysis Patient With Acute Valproic Acid Toxicity

2012 ◽  
Vol 24 (1) ◽  
pp. E18-E19 ◽  
Author(s):  
Emily S. Prohaska ◽  
Andrew J. Muzyk ◽  
Sarah K. Rivelli
Keyword(s):  
Valproic Acid ◽  
Hemodialysis Patient ◽  
Acid Toxicity
Sign in / Sign up

Export Citation Format

Share Document